Alnylam Pharmaceuticals
ALNY
#1123
Rank
A$30.73 B
Marketcap
A$229.44
Share price
3.61%
Change (1 day)
-66.05%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): A$1.77 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$5.01 Billion. In 2025 the company made an earning of A$1.04 Billion, an increase over its 2024 earnings that were of -A$0.35 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.77 B70.31%
2025 A$1.04 B-403.41%
2024 -A$0.35 Billion-24.59%
2023 -A$0.46 Billion-67.84%
2022 -A$1.42 Billion36.93%
2021 -A$1.04 Billion-8.04%
2020 -A$1.13 Billion-15.66%
2019 -A$1.34 Billion12.23%
2018 -A$1.19 Billion62.91%
2017 -A$0.74 Billion17.78%
2016 -A$0.63 Billion43.44%
2015 -A$0.44 Billion60.69%
2014 -A$0.27 Billion98.2%
2013 -A$0.14 Billion
2011 -A$80.06 Million27.48%
2010 -A$62.8 Million-10.92%
2009 -A$70.5 Million95.77%
2008 -A$36.02 Million
2006 -A$57.69 Million-9.13%
2005 -A$63.49 Million34.74%
2004 -A$47.12 Million36.79%
2003 -A$34.45 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$18.46 B 935.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$11.37 B 537.61%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$8.30 B 365.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.2 Billion-110.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$69.27 Million-103.88%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.24 Billion-113.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.78 B 0.21%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-A$0.24 Billion-113.06%๐Ÿ‡บ๐Ÿ‡ธ USA